Research · 2 min read
Ozempic vs Wegovy: One Molecule, Two Different Approvals
They contain the same drug and are made by the same company, and their labels are approved for different things at different maximum doses. That difference is what decides which one a prescriber can write and what a plan will pay for.
Key takeaways
- Same molecule, two separate FDA labels, two different sets of approved uses.
- All three of Ozempic's indications require type 2 diabetes; Wegovy's do not.
- Wegovy is the label carrying weight reduction, including for patients aged twelve and older.
- Maximum doses differ: 2 mg once weekly for Ozempic, 2.4 mg for Wegovy's weight dosing.
- The approved indication is where a plan's rules begin, which is why one molecule can be covered under one benefit and not another.
- That Ozempic's label omits a weight indication is a fact about the document, not a claim that it does not affect weight.
Same molecule, different documents
Both products are semaglutide, and each has its own FDA label. A label is not marketing: it is the document that states what a drug is approved to treat, at what doses, and on what evidence. Two labels for one molecule means two separate approvals, not one drug sold under two names.
Ozempic was first approved in 2017. Wegovy is the later product, and its label is where the weight and cardiovascular-risk indications live.
What each one is approved for
Ozempic's indications section lists three, all of them in adults with type 2 diabetes: as an adjunct to diet and exercise to improve glycemic control; to reduce the risk of major adverse cardiovascular events in patients who also have established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in patients who also have chronic kidney disease.
Wegovy's indications section lists different ones: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining that reduction in adults and in patients aged twelve and older with obesity, and in adults with overweight plus a weight-related condition; and non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, under accelerated approval.
Read the two lists side by side and the distinction is plain. Ozempic's three indications all require type 2 diabetes. Wegovy's do not, and Wegovy is the label that carries weight reduction.
The doses are not the same either
Ozempic starts at 0.25 mg once weekly for four weeks, moves to 0.5 mg, and has a recommended maintenance of 0.5 mg, 1 mg or 2 mg — with a maximum recommended dose of 2 mg once weekly.
Wegovy's weight-reduction dosing runs to 2.4 mg once weekly.
So the two are not interchangeable even at the level of the number on the pen. A person told they are the same drug is being told something true about the molecule and misleading about the product.
Why the distinction shows up on a pharmacy counter
A plan applies its rules to the use a drug is prescribed for, and the approved indication is where that starts. A request written against a diabetes indication and a request written against a weight indication are different requests, even where the molecule is identical.
This site's coverage pages set out the mechanism behind that, including why the same molecule can sit inside one benefit and outside another.
What this page does not say: it does not say Ozempic fails to reduce weight. The label simply does not carry that indication, which is a fact about the document, not a claim about the pharmacology. Anything beyond that is a conversation with a prescriber.
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use — Highlights of Prescribing InformationInitial U.S. Approval: 2017. Section 1, Indications and Usage, all three requiring type 2 diabetes: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. Weight reduction does not appear in this section. Section 2: initiate at 0.25 mg once weekly for 4 weeks, increase to 0.5 mg, recommended maintenance 0.5 mg, 1 mg or 2 mg, maximum recommended dosage 2 mg once weekly.
- WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing InformationSection 1, Indications and Usage: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition; and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, under accelerated approval. None of these requires type 2 diabetes. The 2.4 mg once-weekly dosing is the weight-reduction dose referenced in section 2.
Frequently asked questions
Are Ozempic and Wegovy the same drug?
They contain the same molecule, semaglutide, and each has its own FDA label approving it for different uses at different maximum doses.
Is Ozempic approved for weight loss?
Its indications section does not list weight reduction. All three of its approved indications are in adults with type 2 diabetes. Wegovy is the label that carries the weight indication.
What is the maximum dose of each?
Ozempic's maximum recommended dosage is 2 mg once weekly. Wegovy's weight-reduction dosing runs to 2.4 mg once weekly.
Does either reduce cardiovascular risk?
Both carry a cardiovascular indication, but for different populations: Ozempic in adults with type 2 diabetes and established cardiovascular disease; Wegovy in adults with established cardiovascular disease and either obesity or overweight.
Why does my plan treat them differently?
Because a plan applies its rules to the use a drug is prescribed for, and the approved indication is where that begins. The same molecule can sit inside one benefit and outside another.